Literature DB >> 9050885

Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter.

S Fears1, M Gavin, D E Zhang, C Hetherington, Y Ben-David, J D Rowley, G Nucifora.   

Abstract

The ETV6/CBFA2 (TEL/AML1) fusion gene occurs as a result of the chromosome translocation t(12;21)(p13;q22) in up to 30% of children diagnosed with B cell precursor (cd10+, cd19+) acute lymphoblastic leukemia. Leukemic cells that have acquired the t(12;21) usually demonstrate loss of the remaining normal ETV6 (TEL) allele. Using reporter gene assays we have functionally characterized both the normal ETV6 and ETV6/CBFA2 fusion proteins in the regulation of the MCSFR proximal promoter. Neither ETV6 or ETV6/CBFA2 has any significant, detectable effect on the promoter by itself. However, both ETV6 and ETV6/CBFA2 inhibit the activation of the promoter by CBFA2B(AML1B) and C/EBPa. We have shown that a 29-bp region of the MCSFR promoter containing the binding sites for CBFA2B and C/EBPa is sufficient for the inhibition by ETV6 and ETV6/CBFA2. Mutational analysis of the MCSFR promoter revealed that binding of both CBFA2B and C/EBPa to their respective sites is necessary for the inhibition by ETV6 and ETV6/CBFA2. Deletion of the helix-loop-helix (HLH) region from the cDNAs of ETV6 and ETV6/CBFA2 decreased but did not completely abrogate the ability of either construct to inhibit promoter activation. We also found that the ETS DNA binding region of ETV6 is necessary for inhibition of the promoter. Addition of ETS1 and FLI1, two ETS family members that have homology in the 5' HLH region, but not Spi1, an ETS family member without the 5' HLH region, also inhibited reporter gene expression. Our data show that the inhibition mediated by ETV6 and ETV6/CBFA2, in the context of the MCSFR promoter, depend on interactions with other proteins, not just CBFA2B. Our results also indicate that the transactivation characteristics of ETV6/CBFA2 are a combination of positive and negative regulatory properties.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050885      PMCID: PMC20023          DOI: 10.1073/pnas.94.5.1949

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.

Authors:  P Erickson; J Gao; K S Chang; T Look; E Whisenant; S Raimondi; R Lasher; J Trujillo; J Rowley; H Drabkin
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

2.  The ETV6, CDKN1B and D12S178 loci are involved in a segment commonly deleted in various 12p aberration in different hematological malignancies.

Authors:  I Wlodarska; P Marynen; R La Starza; C Mecucci; H Van den Berghe
Journal:  Cytogenet Cell Genet       Date:  1996

3.  The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor.

Authors:  D E Zhang; C J Hetherington; H M Chen; D G Tenen
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

4.  PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene.

Authors:  E Ogawa; M Maruyama; H Kagoshima; M Inuzuka; J Lu; M Satake; K Shigesada; Y Ito
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

5.  PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells.

Authors:  I Nuchprayoon; S Meyers; L M Scott; J Suzow; S Hiebert; A D Friedman
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

6.  Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.

Authors:  S Wang; Q Wang; B E Crute; I N Melnikova; S R Keller; N A Speck
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

7.  Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

Authors:  T R Golub; G F Barker; M Lovett; D G Gilliland
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

8.  Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha.

Authors:  E Ogawa; M Inuzuka; M Maruyama; M Satake; M Naito-Fujimoto; Y Ito; K Shigesada
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

9.  Cooperative binding of Ets-1 and core binding factor to DNA.

Authors:  D Wotton; J Ghysdael; S Wang; N A Speck; M J Owen
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

10.  Opposing actions of c-ets/PU.1 and c-myb protooncogene products in regulating the macrophage-specific promoters of the human and mouse colony-stimulating factor-1 receptor (c-fms) genes.

Authors:  M A Reddy; B S Yang; X Yue; C J Barnett; I L Ross; M J Sweet; D A Hume; M C Ostrowski
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  17 in total

1.  Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.

Authors:  R Fenrick; J M Amann; B Lutterbach; L Wang; J J Westendorf; J R Downing; S W Hiebert
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.

Authors:  C A Kim; M L Phillips; W Kim; M Gingery; H H Tran; M A Robinson; S Faham; J U Bowie
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.

Authors:  B Lutterbach; D Sun; J Schuetz; S W Hiebert
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement.

Authors:  Timothy Carll; Anand Patel; Benjamin Derman; Elizabeth Hyjek; Angela Lager; Pankhuri Wanjari; Jeremy Segal; Olatoyosi Odenike; Shiraz Fidai; Daniel Arber
Journal:  Blood Adv       Date:  2020-10-13

5.  ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Authors:  Hans-Peter Kantner; Wolfgang Warsch; Alessio Delogu; Eva Bauer; Harald Esterbauer; Emilio Casanova; Veronika Sexl; Dagmar Stoiber
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

6.  The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.

Authors:  J J Westendorf; C M Yamamoto; N Lenny; J R Downing; M E Selsted; S W Hiebert
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

7.  TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1.

Authors:  R Fenrick; L Wang; J Nip; J M Amann; R J Rooney; J Walker-Daniels; H C Crawford; D L Hulboy; M S Kinch; L M Matrisian; S W Hiebert
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9.

Authors:  S R Chakrabarti; R Sood; S Ganguly; S Bohlander; Z Shen; G Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 9.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 10.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.